FDA Approved: ATELVIA — Original Application (Allergan, Inc.)

View source ↗

Summary

FDA approved Atelvia (delayed-release risedronate sodium) under an original NDA from Allergan, for treatment of postmenopausal osteoporosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• ATELVIA (RISENDRONATE SODIUM)

Snippet

ORIG AP for ATELVIA (RISEDRONATE SODIUM)